Abstract
Brain metastasis (BrM) is one of the most common metastases from primary lung cancer (LC). Prior studies have shown that 40% of LC patients develop BrM during the course of their diseases. Recently, the National Lung Screening Trial (NLST) demonstrated that low-dose computed tomography (LDCT) screening (vs chest X-Ray) reduces LC mortality by 20%. This has resulted in USPSTF recommendation of annual LDCT screening for individuals at high risk for LC. Despite the recent adoption of LDCT screening, it remains unknown if early detection of LC through LDCT screening may be potentially beneficial in reducing the risk of developing metastases from primary LC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
